Invivyd (IVVD) Operating Margin (2024 - 2025)
Invivyd posted quarterly Operating Margin of 72.96% for Q4 2025, up 6617.0% year-on-year from 1.09% in Q4 2024, and up 13.1% on a QoQ basis from 83.96% in Q3 2025.
Invivyd (IVVD) has 2 years of Operating Margin data on file, last reported at 72.96% in Q4 2025.
- For the quarter ending Q4 2025, Operating Margin rose 6617.0% year-over-year to 72.96%; the trailing twelve-month figure through Dec 2025 stood at 103.99% (up 59281.0% YoY), and the FY2025 full-year result was 103.99%, up 59281.0% from the prior year.
- Operating Margin for Q4 2025 stood at 72.96%, up from 83.96% in the prior quarter.
- Across five years, Operating Margin topped out at 72.96% in Q4 2025 and bottomed at 2175.22% in Q2 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -6.43% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 38.10% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 17.83% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 23.02% |
| 10 | Invivyd | 208.38 Mn | -18.31 Mn | - | -72.96% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -72.96% |
| Sep 30, 2025 | -83.96% |
| Jun 30, 2025 | -127.78% |
| Mar 31, 2025 | -149.70% |
| Dec 31, 2024 | -139.14% |
| Sep 30, 2024 | -670.01% |
| Jun 30, 2024 | -2,175.22% |